Dyne Therapeutics (DYN) Competitors $14.01 +0.02 (+0.14%) Closing price 04:00 PM EasternExtended Trading$14.01 0.00 (0.00%) As of 05:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends DYN vs. ELAN, TGTX, CYTK, GRFS, VRNA, KRYS, RARE, RNA, SWTX, and ADMAShould you be buying Dyne Therapeutics stock or one of its competitors? The main competitors of Dyne Therapeutics include Elanco Animal Health (ELAN), TG Therapeutics (TGTX), Cytokinetics (CYTK), Grifols (GRFS), Verona Pharma (VRNA), Krystal Biotech (KRYS), Ultragenyx Pharmaceutical (RARE), Avidity Biosciences (RNA), SpringWorks Therapeutics (SWTX), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry. Dyne Therapeutics vs. Elanco Animal Health TG Therapeutics Cytokinetics Grifols Verona Pharma Krystal Biotech Ultragenyx Pharmaceutical Avidity Biosciences SpringWorks Therapeutics ADMA Biologics Elanco Animal Health (NYSE:ELAN) and Dyne Therapeutics (NASDAQ:DYN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, community ranking, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment. Do institutionals & insiders hold more shares of ELAN or DYN? 97.5% of Elanco Animal Health shares are owned by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are owned by institutional investors. 0.6% of Elanco Animal Health shares are owned by insiders. Comparatively, 20.8% of Dyne Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the MarketBeat Community believe in ELAN or DYN? Elanco Animal Health received 102 more outperform votes than Dyne Therapeutics when rated by MarketBeat users. However, 75.51% of users gave Dyne Therapeutics an outperform vote while only 54.51% of users gave Elanco Animal Health an outperform vote. CompanyUnderperformOutperformElanco Animal HealthOutperform Votes13954.51% Underperform Votes11645.49% Dyne TherapeuticsOutperform Votes3775.51% Underperform Votes1224.49% Does the media refer more to ELAN or DYN? In the previous week, Elanco Animal Health had 8 more articles in the media than Dyne Therapeutics. MarketBeat recorded 10 mentions for Elanco Animal Health and 2 mentions for Dyne Therapeutics. Dyne Therapeutics' average media sentiment score of 0.38 beat Elanco Animal Health's score of 0.18 indicating that Dyne Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Dyne Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, ELAN or DYN? Elanco Animal Health has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500. Comparatively, Dyne Therapeutics has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Do analysts rate ELAN or DYN? Elanco Animal Health currently has a consensus price target of $16.00, indicating a potential upside of 45.24%. Dyne Therapeutics has a consensus price target of $49.91, indicating a potential upside of 256.24%. Given Dyne Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Dyne Therapeutics is more favorable than Elanco Animal Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Elanco Animal Health 1 Sell rating(s) 4 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.25Dyne Therapeutics 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.08 Is ELAN or DYN more profitable? Elanco Animal Health has a net margin of 4.60% compared to Dyne Therapeutics' net margin of 0.00%. Elanco Animal Health's return on equity of 6.78% beat Dyne Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Elanco Animal Health4.60% 6.78% 3.03% Dyne Therapeutics N/A -57.46%-51.62% Which has stronger valuation & earnings, ELAN or DYN? Dyne Therapeutics has lower revenue, but higher earnings than Elanco Animal Health. Dyne Therapeutics is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioElanco Animal Health$4.42B1.23-$1.23B$0.4027.54Dyne TherapeuticsN/AN/A-$235.94M-$3.56-3.94 SummaryElanco Animal Health beats Dyne Therapeutics on 10 of the 18 factors compared between the two stocks. Get Dyne Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DYN vs. The Competition Export to ExcelMetricDyne TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.43B$7.04B$5.77B$8.95BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-3.946.1326.4918.81Price / SalesN/A314.26449.1576.66Price / CashN/A67.8344.0437.47Price / Book9.406.747.634.64Net Income-$235.94M$138.11M$3.18B$245.69M7 Day Performance0.72%-2.02%-1.82%-2.64%1 Month Performance-3.71%-1.54%0.22%-2.37%1 Year Performance-37.87%-3.14%17.49%13.63% Dyne Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DYNDyne Therapeutics3.0828 of 5 stars$14.01+0.1%$49.91+256.2%-38.5%$1.43BN/A-3.94100ELANElanco Animal Health4.1542 of 5 stars$11.50-0.2%$16.29+41.7%-31.0%$5.69B$4.42B28.769,300Analyst ForecastTGTXTG Therapeutics4.4888 of 5 stars$32.11-3.0%$40.67+26.7%+133.9%$5.04B$233.66M-323.50290Positive NewsCYTKCytokinetics4.1946 of 5 stars$42.27-1.1%$83.00+96.4%-33.5%$4.99B$7.53M-7.87250GRFSGrifols2.1748 of 5 stars$6.99-1.9%N/A-11.8%$4.81B$7.01B0.0023,737VRNAVerona Pharma1.9573 of 5 stars$58.96-2.2%$53.14-9.9%+277.6%$4.72B$460,000.00-30.7330KRYSKrystal Biotech4.4939 of 5 stars$154.88+0.0%$206.67+33.4%+63.6%$4.45B$50.70M87.50210Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageRAREUltragenyx Pharmaceutical4.6169 of 5 stars$44.91-1.0%$92.43+105.8%-7.1%$4.16B$522.75M-6.961,276Analyst ForecastRNAAvidity Biosciences1.6234 of 5 stars$34.09-2.4%$65.80+93.0%+132.7%$4.06B$9.56M-11.81190SWTXSpringWorks Therapeutics1.2638 of 5 stars$54.05+34.2%$70.00+29.5%+22.8%$4.02B$5.45M-13.93230Earnings ReportAnalyst ForecastInsider TradeNews CoverageHigh Trading VolumeADMAADMA Biologics3.5399 of 5 stars$16.64-0.4%$21.25+27.7%+212.2%$3.93B$258.21M59.44530 Related Companies and Tools Related Companies Elanco Animal Health Competitors TG Therapeutics Competitors Cytokinetics Competitors Grifols Competitors Verona Pharma Competitors Krystal Biotech Competitors Ultragenyx Pharmaceutical Competitors Avidity Biosciences Competitors SpringWorks Therapeutics Competitors ADMA Biologics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:DYN) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyne Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dyne Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
